Drug, across the briefings
Regorafenib across 19 cancers
Regorafenib appears in 19 of the briefings; its FDA label names 4 of those diseases.
| Disease | FDA label | Open Targets stage, on which gene | Trials | Active |
|---|---|---|---|---|
| Colorectal cancer | label names disease | phase 4 on BRAF, NTRK1 | 143 | 41 |
| Gastrointestinal stromal tumour | label names disease | phase 4 on KIT, PDGFRA, BRAF | 24 | 10 |
| Hepatocellular carcinoma | label names disease | phase 4 on KDR | 48 | 24 |
| Small intestine cancer | label names disease | phase 4 on BRAF, KIT, PDGFRA | — | — |
| Acute lymphoblastic leukemia | phase 4 on ABL1 | 2 | 0 | |
| Acute myeloid leukemia | phase 4 on KIT | 4 | 0 | |
| Cholangiocarcinoma | phase 4 on FGFR2, BRAF | 6 | 1 | |
| Chronic myeloid leukemia | phase 4 on ABL1 | 1 | 0 | |
| Gallbladder cancer | phase 4 on FGFR2 | 2 | 0 | |
| Gastric cancer | phase 4 on FGFR2, KDR | 5 | 1 | |
| Glioblastoma | phase 4 on PDGFRA | 7 | 2 | |
| Kidney cancer | phase 4 on KDR | 5 | 1 | |
| Lower-grade glioma | phase 4 on PDGFRA | — | — | |
| Lung cancer | phase 4 on BRAF, RET, NTRK1 | 8 | 3 | |
| Melanoma | phase 4 on BRAF, KIT | 5 | 1 | |
| Osteosarcoma | phase 4 on KDR | 7 | 4 | |
| Soft tissue sarcoma | phase 4 on PDGFRA, NTRK1, PDGFRB | 8 | 2 | |
| Testicular cancer | phase 4 on KIT | — | — | |
| Thyroid cancer | phase 4 on BRAF, RET, NTRK1 | 2 | 0 |
The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.